SWP
LCTX icon

Stratos Wealth Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Stratos Wealth Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,516
Closed -$22K – 1746
2018
Q3 		$22K Buy
+10,516
New +$22.1K ﹤0.01% 1830
2018
Q2 		– Sell
-5,944
Closed -$14K – 1869
2018
Q1 		$14K Buy
5,944
+3,086
+108% +$7.24K ﹤0.01% 2166
2017
Q4 		$5K Buy
+2,858
New +$6.24K ﹤0.01% 2393

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Stratos Wealth Partners's LCTX Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Lineage Cell Therapeutics (LCTX) in Q4 2018, closing a stake of 10,516 shares — an estimated $22K sold.

Stratos Wealth Partners first reported a position in LCTX in Q4 2017 and held it in 3 quarters. The position peaked at $22K in Q3 2018. 105 funds tracked by Wall St. Rank hold LCTX as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Lineage Cell Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 10,516 Lineage Cell Therapeutics shares in Q4 2018, an estimated $22K.
  • Stratos Wealth Partners first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's Lineage Cell Therapeutics position peaked at $22K in Q3 2018.
  • 105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.